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Abstract
Background: Gestational choriocarcinoma is a rare malignancy believed to arise from the trophoblast cells of the
placenta. Despite the frequently aggressive clinical nature, choriocarcinoma has been routinely curable with
cytotoxic chemotherapy for over 50 years. To date little is known regarding the route to oncogenesis in this
malignancy.
Methods: In a case of intraplacental choriocarcinoma, we have performed detailed genetic studies including
microsatellite analysis, whole genome sequencing (WGS) and methylation analysis of the tumour and surrounding
mature placenta.
Results: The results of the WGS sequencing indicated a very low level of mutation and the absence of any driver
mutations or oncogene activity in the tumour. The methylation analysis identified a distinctly different profile in the
tumour from that of the mature placenta. Comparison with a panel of reference methylation profiles from different
stages of placental development indicated that the tumour segregated with the first trimester samples.
Conclusions: These findings suggest that gestational choriocarcinoma is likely to arise as a result of aberrations of
methylation during development, rather than from DNA mutations.
The results support the hypothesis that gestational choriocarcinoma arises from a normally transient early
trophoblast cell. At this point in development this cell naturally has a phenotype of rapid division, tissue
invasion and sensitivity to DNA damaging chemotherapy that is very similar to that of the mature
choriocarcinoma cell.
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Background
Gestational Trophoblastic Neoplasia (GTN) are a
group of rare conditions that arise from the cells of
conception. The most frequent forms are the pre-ma-
lignant genetically abnormal complete and partial
hydatidiform moles which arise from an androgenetic
or triploid dispermic conceptus respectively. The
clinically more complex malignant diagnoses of gesta-
tional choriocarcinoma, placental site trophoblastic
tumour (PSTT) and epithelioid trophoblastic tumour
(ETT), whilst on occasion can arise from a molar
pregnancy, more usually each arise from pregnancies
that have the normal genetic complement [1].
Clinically gestational choriocarcinoma is frequently char-
acterised as an invasive, fast growing and aggressive cancer.
Presentation during the causative pregnancy is rare and
most cases are identified some months or years following
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the causative pregnancy often as a result of symptoms from
distant metastatic spread. The overall incidence of gesta-
tional choriocarcinoma is estimated at 1 case per 50,000
pregnancies and aside from increasing maternal age does
not appear to have any other significant risk factors [2].
Despite this rarity and the rapidity of cell growth,
gestational choriocarcinoma has been curable with cyto-
toxic chemotherapy since the 1950s and in modern
series the overall cure rate now approaches 95% [3, 4].
Conventionally malignancies characteristically arise
from previously normal cells that develop the malig-
nant phenotype, including uncontrolled growth and
invasion, as a result of a number of DNA mutations
[5]. The normally transient early trophoblast cells
have a phenotype, including rapid growth, local inva-
sion and stimulation of angiogenesis that is similar
to that of a malignant cell. As a result, it has been
suggested that gestational choriocarcinoma may not
necessarily represent a classical mutation based ma-
lignant transformation. Instead these tumours could
arise due to the persistence of early trophoblast
cells, which have failed to either mature or undergo
apoptosis [6].
In contrast to most common malignancies, gestational
choriocarcinoma is frequently managed based on a clinical
diagnosis without a biopsy and therefore tumour samples
of sufficient quantity to permit detailed genetic or methyla-
tion analysis are exceptionally rare. As a result, no previous
whole genome sequencing or detailed methylation studies
have been reported for this rare diagnosis.
Gestational choriocarcinoma is thought to originate
from the cytotrophoblast and syncytiotrophoblast cells
that develop into the placenta. Since most cases are not
diagnosed until months or years after the end of the
pregnancy, in the large majority of cases of choriocarcin-
oma the placenta has been discarded before the diagno-
sis is clinically apparent. However, in very rare cases an
intra-placental choriocarcinoma is noted within the pla-
centa at delivery or on pathological examination. This is
therefore the earliest clinical time point for diagnosis of
a choriocarcinoma and such material provides a unique
opportunity to study the genetic or epigenetic changes
that could drive the malignant behaviour of this tumour
prior to any additional later acquired changes. Interest-
ingly, even in these ‘early’ choriocarcinomas approxi-
mately 50% are already associated with metastatic
spread. Fortunately, with modern chemotherapy the cure
rate for women with these rare intraplacental choriocar-
cinomas approaches 100% [7].
Here we have investigated the potential contribution
of genetic and epigenetic changes to the pathogenesis of
this rare malignancy, using whole genome sequencing
and methylation analysis from a recent case of intrapla-
cental gestational choriocarcinoma.
Case presentation
After an uneventful second pregnancy a 41-year-old
caucasian woman delivered a 39-week female baby
via emergency caesarean section for fetal distress. At
delivery the baby was unwell and despite resuscita-
tion, sadly died 19 h post-delivery.
Macroscopic examination of the placenta demonstrated a
4 cm abnormality (Fig. 1a). On histopathological review the
diagnosis of gestational choriocarcinoma was made based
on the morphological appearance of sheets of atypical
mononucleated cytotrophoblast admixed with multinucle-
ated syncytiotrophoblast with associated haemorrhage and
necrosis (Fig. 1b). A fetal post mortem was not performed.
In response to the diagnosis of choriocarcinoma, the
patient was assessed for the presence of metastatic dis-
ease with an MRI scan of the head and pelvis and a CT
of the chest and abdomen and serial serum human
chorionic gonadotrophin (hCG) monitoring. The im-
aging showed no evidence of distant disease. The hCG
level immediately post-partum was 202,499 IU/L and
then fell sequentially with the expected 1–2 day half-life
(A)
(B)
Fig. 1 Pathology of intraplacental choriocarcinoma. a Gross
morphology of choriocarcinoma within the normal placenta. b
Haematoxylin and eosin stained section of tumour (right) and
surrounding normal placenta (left)
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for complete removal of tumour reaching the normal
range approximately 30 days post-delivery. On follow up
the patient has remained well, with a normal serum




With the patient’s consent and in keeping with the insti-
tutional ethics policy further genetic analysis of the pla-
centa and tumour were performed.
Preparation of genomic DNA
With reference to a consecutive haematoxylin and eosin
stained section, tumour tissue and surrounding normal
placenta were micro-dissected independently from un-
stained formalin-fixed paraffin-embedded (FFPE) sec-
tions. DNA was prepared from dissected tissue using a
QIAmp DNA FFPE Tissue Kit (Qiagen, UK) and the
DNA quantified using a Picogreen dsDNA quantitation
kit (Life Technologies, UK).
Fluorescent microsatellite genotyping
To exclude the possibility that the tumour could have
been either a metastasis from an occult cancer, a gesta-
tional choriocarcinoma from previous pregnancy or have
arisen from a concurrent hydatidiform mole genotyping
of DNA from the tissue and normal surrounding pla-
centa was performed [8]. Briefly, 5 ng of DNA from the
normal placenta and tumour tissue were amplified with
a panel of primers for 15 short tandem repeat (STR) loci
on 13 autosomes and the amelogenin locus using an
AmpFlSTR Identifiler Plus kit (Applied Biosystems,
Warrington, UK). PCR products were resolved by capil-
lary electrophoresis using an ABI 3100 Genetic Analyser
and genotypes determined using GeneMapper version
5.0 software (Applied Biosystems).
Whole genome sequencing
Genomic DNA libraries were prepared following Illumina’s
(Illumina, San Diego, CA) suggested protocol and
sequenced by Hiseq X Ten (Illumina) with 150PE. Somatic
variants were identified using GATK Best Practices Pipeline.
After Illumina sequencing, all produced FASTQ reads were
quality-checked and trimmed with FastQC (version 0.11.2
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/)
and Trimmomatic (version 0.33). The average coverage of
each base in the genome was 36.31 for the tumours and
23.11 for the placenta. The Q30 (%) was 91.20%. Sequencing
reads were aligned to human genome hg19 with the BWA
MEM software for both tumour and normal samples. PCR
duplications of each BAM file were marked with Picard soft-
ware (version 1.103 https://broadinstitute.github.io/picard/).
The BAM files were locally realigned, and the base quality
scores were recalibrated with GATK (version 3.1). Single
nucleotide variants and Indels were detected using MuTect
(version 1.1.6) and Strelka (version 1.0.14) respectively. All
the somatic variants were validated with Integrative
Genomics Viewer and annotated with Variant Effect Pre-
dictor (version 83).
Methylation array hybridization
FFPE-derived DNA from both the tumour and placenta tis-
sue were hybridized to the Illumina Infinium Methylation
EPIC (EPIC) arrays. Bisulphite conversion was performed
according to the manufacturer’s recommendations for the
Illumina Infinium Assay (EZ DNA methylation kit, ZYMO,
Orange, CA) and subjected to the Infinium FFPE QC and
restoration kit prior to hybridisation.
Data filtering and analysis of methylation signals
Before analysing the data, possible sources of technical
biases that could influence results were excluded. We
applied signal background subtraction using default control
probes in BeadStudio (version 2011.1_Infinium HD). We
discarded probes with a detection P-value > 0.01, contain-
ing single nucleotide polymorphisms (SNPs) within the
interrogation or extension base as well as those with poten-
tial cross-reaction due to multiple sequence homologies.
We also excluded probes that lacked signal values in one or
more of the DNA samples analysed and that mapped to the
X & Y chromosomes. In total 772,399 probes were investi-
gated. For the analysis of known imprinted ubiquitous
differentially methylated regions (DMRs), probes mapping
to the intervals identified by Hernandez-Mora et al. were
directly examined [9]. The names of each region are in
accordance with the recently recommended nomenclature
for clinical reporting of imprinted methylation profiles [10].
For placenta-specific imprinted DMRs, only probes map-
ping to regions with confirmed allelic methylation were
interrogated [11]. The common regions of CpG island
Methylator Phenotype (CIMP) were taken from Martin-
Trujillo et al. [12]. In-house bioinformatics R scripts were
utilized for statistics to identify loci with different methyla-
tion profiles between the two samples and to compare the
FFPE-derived DNA methylation profiles with those
obtained from high-molecular weight DNAs extracted dir-
ectly from paired first trimester chorionic villous samples
and term biopsies (GEO repository GSE121056) [13]. The
data from the FFPE placenta and tumour are available in
the GEO repository with the accession number
GSE125386.
Bisulphite methylation analyses
For confirmation PCR analyses, loci with the greatest sig-
nificant difference identified using the EPIC arrays were tar-
geted using standard bisulphite PCR. Furthermore, these
and those analysed by pyrosequencing, had underlying
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converted sequences compatible with optimal primer de-
sign resulting in short products incorporating numerous
CpG dinucleotides to ensure efficient amplification in
FFPE-degraded input DNA.
Allelic PCR: Approximately 1 μg FFPE-derived DNA was
converted using the EZ DNA Methylation-Gold kit (Zymo)
following manufacturer’s instructions for short incubation
times to avoid additional fragmentation of the DNA during
the treatment. Approximately 5 μl of bisulphite converted
DNA was used in each amplification reaction using Immo-
lase Taq polymerase (Bioline, UK) for 45 cycles and the
resulting PCR product sub-cloned into pGEM-T easy
vector (Promega) for sequencing (for primer sequences see
Additional file 1: Table S1).
Pyrosequencing: Standard bisulphite PCR was used
to amplify 50 ng of bisulphite converted DNA with the
exception that one primer was biotinylated (for primer
sequence see Additional file 1: Table S1). The entire
biotinylated PCR product (diluted to 40 μl) was mixed
with 38 μl of Binding buffer and 2 μl (10 mg/ml) strep-
tavidin-coated polystyrene beads. After incubation at
65 °C, DNA was denatured with 50 μl 0.5 M NaOH.
The single-stranded DNA was hybridized to 40-pmol
sequencing primers dissolved in 11 μl annealing buffer
at 90 °C. For sequencing, a primer was designed to the
opposite strand to the biotinylated primer used in the
PCR reaction. The pyrosequencing reaction was car-
ried out on a PyroMark Q96 instrument. The peak
heights were determined using Pyro Q-CpG1.0.9 soft-
ware (Biotage, Sweden).
Results
Fluorescent microsatellite genotyping analysis
The fluorescent microsatellite genotyping analysis
(Additional file 2: Table S2) demonstrated the tumour
to have the same genotype as the healthy placenta,
confirming the identity of the tumour as a non-molar
gestational choriocarcinoma arising in the current
pregnancy. Furthermore, these results were endorsed
by analysis of 65 highly informative SNPs present on
the Illumina EPIC methylation array.
Whole genome sequencing
Whole genome sequencing did not demonstrate any mu-
tations of the common cancer associated oncogenes or
any other driver mutations. The overall mutational load
was extremely low, both in the number of detected muta-
tions and also the proportion of the DNA prepared from
the malignant cells that carry any of these apparent muta-
tions (Table 1). Overall the results indicate that within this
tumour the mutational load was extremely low and un-
likely to be of biological significance.
Methylation studies
In contrast the epigenetic studies demonstrated that
the pattern of methylation is markedly different be-
tween the tumour, the surrounding normal placenta
or reference unrelated term placental samples. To de-
termine whether there was any resemblance of the
methylation profile in the tumour with early placental
samples we obtained DNA from 12-week chorionic
villus biopsies. Interestingly, using both partitioning
and hierarchical clustering, we observed that the
tumour has a genome-wide methylation profile resem-
bling the first trimester chorionic villous samples,
whilst the placenta is located in a separate branch
with normal term controls (Fig. 2a). To identify spe-
cific loci that are differentially methylated between
the tumour and placenta we performed an unsuper-
vised search between the two samples. This revealed
177816 hypermethylated positions and 405383 hypo-
methylated by −/+ 2.5% (0.025ß), the accepted detection
resolution of the Infinium assays [14]. Of these 336 dif-
fered by more than 50% (0.5ß) (Fig. 2b). Subsequently we
performed bumphunter analysis to identify multiple probe
clusters of which 2645 were hypermethylated and 3365
hypomethylated (Additional file 3: Table S3). In general,
hypermethylated intervals were larger (top 200 candidates;
mean length 877 bp SD 594 bp, containing on average
10.4 probes) than hypomethylated regions (top 200 candi-
dates; mean length 257 bp SD 325 bp containing on aver-
age 3.5 probes), however these differences may reflect a
bias in assay design since probes in intergenic regions are
underrepresented. When the genomic location of the dif-
ferentially methylated probes is taken into consideration,
“CpG island” probes are clearly less prone to be hypo-
methylated in the tumour with respect to the placenta,
while “CpG islands, shelf and shores” are hypermethylated
(Fig. 2c). To validate the methylation profiles obtained
from the EPIC array comparisons we performed bisulphite
PCR and sub-cloning of two regions. In each case we con-
firm the profile observed, with TLL1 and ZNF350 being
more methylated in the tumour than placenta (Fig. 2d).
Next, we analysed the methylation profiles at
imprinted differentially methylated regions (DMRs)
since these are closely linked to both placental de-
velopment and tumourigenesis [15]. Of the 40 ubi-
quitous imprinted DMRs present on the EPIC
platform loss-of-methylation (LOM) was far more
frequent than gains-of-methylation (GOM) with 18
regions comparable between the two samples, 16
modestly hypomethylated and 6 hypermethylated in
the tumour (Fig. 2e, Additional file 4: Table S4). One
region of GOM, at the paternally-methylated ZDBF2
DMR is as a direct consequence of hypomethylation
of the adjacent maternally-methylated GPR1-AS1
DMR which is responsible for appropriate allelic
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methylation at this domain in a hierarchical manner
[16]. To ensure the EPIC array data truly reflects the
methylation profile at imprinted DMRs, we
performed pyrosequencing for the H19, KCNQ1OT1,
and FAM50B regions which confirmed that the







Fig. 2 Characterization of DNA methylation in the placenta and tumour using the Illumina EPIC methylation array. a Hierarchical clustering of
global methylation for placenta-tumour paired samples with 8 term placenta and 2 first trimester CVS samples. b Bar graph of the distribution of
the hypo- (left side) and hypermethylated (right side) probes with a difference greater that −/+ 2.5% (0.025ß) when comparing the tumour and
paired placenta. c Classification of probes with differential methylation according to genomic location. The bar chart illustrates probe enrichment
classified by Illumina Infinium annotation. d Bisulphite confirmation of methylation difference between tumour and paired placenta samples. Each
circle represents a single CpG dinucleotide on a DNA strand. (•) Methylated cytosine, (o) unmethylated cytosine. Each row corresponds to an
individual cloned sequence. e Heatmap of the ubiquitous imprinted DMR probes in control first trimester CVS and term placenta biopsies as well
as the tumour and paired placenta samples. The values represent the average of all probes mapping to each region. f Methylation levels of
ubiquitous imprinted DMRs in the placenta (green dot), tumour (red dot) and controls (violin plots n = 16) quantified by pyrosequencing
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corresponding placenta (Fig. 2f ). We subsequently
extended this analysis to placenta-specific imprinted
DMRs. Of the samples with appropriate methylation
in the placenta samples (these are polymorphic
epialleles so we only analysed those with a pattern
consistent with allelic methylation in the normal
placenta sample), 97 regions were comparable be-
tween the two samples and 69 modestly hypomethy-
lated (Additional file 5: Table S5), with the levels at
the CMTM3 and GLIS3 DMRs confirmed by pyrose-
quencing (Additional file 7: Figure S1A and B).
Finally, potential changes in methylation associated
with the tumourigenic process have previously been re-
ported in samples with global hypomethylation. Wide-
spread CpG island promoter hypermethylation, also
referred to as CpG island methylator phenotype (CIMP),
has been reported for many tumour types [17]. With the
exception of CRABP1, the analysis of 23 CIMP regions
revealed very little tumour-associated hypermethylation
(Additional file 7: Figure S1C, Additional file 6: Table
S6) suggesting that CIMP may not be a universal
phenomenon in gestational choriocarcinomas.
Discussion
To date there has been relatively little work examining
the potential role of genetic changes in the pathogenesis
of gestational tumours. However, recent data from tar-
geted sequencing of 6 cases of gestational choriocarcin-
oma, examining 637 cancer related genes, has indicated
an extremely low level of somatic mutation [18]. Simi-
larly targeted sequencing of cases of the PSTT and ETT,
gestational malignancies that arise slightly later in pla-
cental development, have also demonstrated very low
levels of mutation and a lack of any repetitive or driver
mutations [19].
Intra-placental gestational choriocarcinomas, in
which the tumour is identified in the placenta during
pregnancy or at delivery are extremely rare but
represent a very early form of gestational malignancy
[7]. As a result, any genetic changes identified in an
intra-placental gestational choriocarcinoma are likely
to represent the earliest changes associated with
tumour development.
In this report, we have aimed to more fully charac-
terise the genetic and epigenetic changes in a case of
intra-placental gestational choriocarcinoma. We first
confirmed the gestational origin of the malignancy
found within the placenta by microsatellite genotyp-
ing analysis, the results shown in Additional file 2:
Table S2 demonstrate identical results at all 16 loci.
This result excludes the possibility that the tumour
in the placenta could either have been a metastasis
from an occult primary cancer or have arisen from a
prior conception or concurrent molar pregnancy.
Further analysis by whole genome sequencing of the
tumour with comparison to the neighbouring healthy
placenta failed to demonstrate any mutations in any
established oncogenes or any appreciable mutations else-
where in the genome as shown in Table 1. This finding,
a lack of any significant mutation in this case, supports
the earlier genetically bland findings obtained from se-
quencing of a limited number of genes in a panel of
trophoblast tumours [18, 19]. A number of paediatric ma-
lignancies, which each share a relatively short oncogenesis
timeframe, similarly have very low overall levels of muta-
tions. In these other rare diagnoses, the cells gain their
malignant phenotype from single driver mutations in the
case of infantile acute lymphoblastic leukaemia and paedi-
atric rhabdoid tumours or epigenetic changes alone in
CIMP-positive ependymoma [20–22].
It is apparent that the time frame for the development
of malignancy in gestational choriocarcinoma is even
shorter than for these paediatric malignancies. We have
previously questioned whether accumulation of muta-
tions, as in the common epithelial malignancies, could
be the route to oncogenesis of this rare malignancy [6].
The demonstration of a lack of significant mutation in
this case analysed by WGS and in other cases of tropho-
blast tumours previously analysed by limited genomic
profiling would support the argument that gestational
choriocarcinoma does not appear to be a mutation
driven malignancy [18, 19].
Normal early trophoblast cells appear to share many
characteristics of malignant choriocarcinoma cells in-
cluding rapid proliferation, hCG production, an ability
to invade into other tissues, stimulation of angiogenesis
and also the extreme sensitivity to DNA damaging
chemotherapy [23, 24]. As a result, it has been hypothe-
sised that gestational choriocarcinoma may occur not as
a result of genetic change but via the inappropriate per-
sistence of normally transient primitive trophoblast cells,
that are unable to either mature or undergo apoptosis.
As a result, these cells could be locked in a frozen devel-
opmental state of an early trophoblast cell’s and retain
much of that cells normal phenotypically malignant
phenotype [6].
In the absence of a mutational cause for oncogenesis
we examined the methylation status of the tumour
DNA. Normal placental development is associated with
wide spread epigenetic changes, the transition from first
to third trimester being associated with increasing
hypermethylation [25–27]. Examination of the methyla-
tion profile using high-throughput arrays of the tumour
and normal placenta in the current case showed the
methylation patterns of the tumour and the mature pla-
centa differ significantly (Fig. 2). The tumour sample
was hypomethylated compared to the placenta at most
ubiquitous and placenta imprinted DMRs. Despite the
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differences detected using EPIC methylation arrays being
modest, validation using quantitative pyrosequencing
revealed a similar degree of hypomethylation at three
ubiquitous and two placenta specific imprinted DMRs.
Hierarchical clustering demonstrated the tumour to
cluster with first trimester chorionic villous samples
while the placenta clustered with the term controls. This
demonstration that the methylation profile of the
tumour is close to that of a first trimester placenta ra-
ther than a mature placenta supports the hypothesis that
gestational choriocarcinoma arises from an early tropho-
blast cell [23].
The biological processes involved in early pregnancy
share several phenotypic hallmarks of cancer. After
undergoing epithelial-to-mesenchymal transition, pla-
cental cells invade and migrate within the endometrium
whilst evading maternal immune system. The similarities
between placenta development and cancer also extends
to their unusual epigenomes. Recently, Nordor and col-
leagues reported that loci undergoing widespread hypo-
methylation in placenta were of similar size and location
as those distinguishing tumours from matched normal
tissues [28].
In addition to the widespread intergenic hypomethyla-
tion evident in this case of intra-placental gestational
choriocarcinoma, many promoter CpG islands under-
went hypermethylation. Promoter hypermethylation of
tumour-suppressor genes is a frequent and key event in
tumorigenesis. Of the promoters gaining methylation in
our sample, many have already been shown to have
tumour suppressor activity, including RORa, FAN1,
PRDM1, CYGB, L3MBTL4, EPB41L3, with ZNF471 and
ZNF671 being specifically silenced by methylation [29, 30].
Strikingly, like ZNF471 and ZNF671, 27 of the top 200
hypermethylated genes identified in this study map to zinc-
finger genes, with 75% mapping to the Chr19q41–43
cluster, suggesting that altered expression of these DNA-
binding proteins maybe involved in the development of
gestational choriocarcinoma.
The concept that the onset of malignancy can cause a
halt in the normal developmental pathways and prevent
onset of the normal processes of apoptosis is well estab-
lished in the lymphoid malignancies [31]. The impact of
stopping the normal development of the trophoblast cell
at the time of transformation to the choriocarcinoma
cell, may explain the extreme sensitivity of these malig-
nant cells to DNA damaging chemotherapy drugs. This
characteristic of normal early trophoblast cells is
exploited in the medical management of ectopic preg-
nancy which is effectively treated with low doses of the
chemotherapy agent methotrexate [32].
The ability of methylation changes alone to result in
oncogenesis has already been demonstrated in CIMP-
positive ependymoma, a rare malignancy occurring in
children. Studies looking at a panel of these tumours
have demonstrated that there are only overall very low
levels of mutations with no discernable patterns or
driver mutations [22]. In this form of ependymoma it
appears that the production of the malignant phenotype
occurs via epigenetic changes including transcriptional
silencing of key developmental genes.
It is difficult to draw firm conclusions based on the
genome analysis of FFPE material from a single case of
intraplacental gestational choriocarcinoma. However,
our data suggest that the malignant phenotype in this
diagnosis, as in ependymomas, may be based on epigen-
etic rather than genetic changes. We predict that the
changes at imprinted loci lead to a block in the develop-
ment of early trophoblast cells at a stage where their
phenotype is naturally close to that of a malignant cell.
The importance of the differing basic physiology of the
cell origin in determining the sensitivity to cytotoxic
chemotherapy is clearly demonstrated in these two ma-
lignancies that occur without DNA mutations. Whilst
gestational choriocarcinoma is extremely sensitive to
chemotherapy and highly curable, CIMP ependymoma
which is also methylation driven and has no mutations
is extremely resistant to chemotherapy and carries a very
poor prognosis [33].
Conclusions
Based on the initial data available from this case it
may be possible to suggest an important difference
in the route to oncogenesis between gestational
choriocarcinoma and other malignancies. Character-
istically malignancies gain their malignant phenotype
as a result of an aberrant genetic event. In contrast
it appears that in gestational choriocarcinoma the
cells do not gain the malignant phenotype, but they
fail to lose the essentially malignant phenotype of a
primitive trophoblast cell as a result of an aberrant
event in the normal progression of methylation
changes.
The natural history of gestational choriocarcinoma
is extremely varied. The interval from pregnancy to
presentation can be very short or can extend to
greater than 20 years. Similarly, the clinical course
can vary from a widely metastatic fast growing and
life-threatening cancer to one that has more indolent
behaviour presenting with repeated false positive
pregnancy tests, but without clinical symptoms. It is
likely that this width of clinical behaviour may be
matched by differing patterns of methylation and
gene expression. Further studies examining the role
of methylation changes in other cases of tropho-
blastic tumours may provide confirmation of these
observations and also a more detailed understanding
of this route to oncogenesis.
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